S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:CERE

Cerevel Therapeutics (CERE) Stock Price, News & Analysis

$40.88
-0.18 (-0.44%)
(As of 02/23/2024 ET)
Today's Range
$40.86
$41.14
50-Day Range
$40.93
$43.27
52-Week Range
$19.59
$43.59
Volume
1.03 million shs
Average Volume
1.80 million shs
Market Capitalization
$7.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.64

Cerevel Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.18 Rating Score
Upside/​Downside
3.0% Downside
$39.64 Price Target
Short Interest
Bearish
6.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.40mentions of Cerevel Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$2.53 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.50) to ($2.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.71 out of 5 stars

Medical Sector

841st out of 939 stocks

Pharmaceutical Preparations Industry

395th out of 439 stocks


CERE stock logo

About Cerevel Therapeutics Stock (NASDAQ:CERE)

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CERE Stock Price History

CERE Stock News Headlines

Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
AbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel
Cerevel Therapeutics (NASDAQ:CERE) PT Raised to $45.00
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
AbbVie Cuts Its Guidance on ImmunoGen Deal
Cerevel Therapeutics Holdings Inc (CERE)
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
AbbVie 4Q Sales Lower as Humira Revenue Sinks
Top Picks 2024- Celldex Therapeutics CLDX
See More Headlines
Receive CERE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
2/23/2024
Next Earnings (Estimated)
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Coal & Consumable Fuels
Current Symbol
NASDAQ:CERE
CUSIP
15677310
Fax
N/A
Employees
321
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.64
High Stock Price Target
$45.00
Low Stock Price Target
$22.00
Potential Upside/Downside
-3.0%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
11 Analysts

Profitability

Net Income
$-351,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.33 per share

Miscellaneous

Free Float
171,084,000
Market Cap
$7.37 billion
Optionable
Optionable
Beta
1.54
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives















CERE Stock Analysis - Frequently Asked Questions

Should I buy or sell Cerevel Therapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CERE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERE, but not buy additional shares or sell existing shares.
View CERE analyst ratings
or view top-rated stocks.

What is Cerevel Therapeutics' stock price target for 2024?

11 analysts have issued 12 month price targets for Cerevel Therapeutics' stock. Their CERE share price targets range from $22.00 to $45.00. On average, they anticipate the company's stock price to reach $39.64 in the next twelve months. This suggests that the stock has a possible downside of 3.0%.
View analysts price targets for CERE
or view top-rated stocks among Wall Street analysts.

How have CERE shares performed in 2024?

Cerevel Therapeutics' stock was trading at $42.40 at the beginning of 2024. Since then, CERE shares have decreased by 3.6% and is now trading at $40.88.
View the best growth stocks for 2024 here
.

Are investors shorting Cerevel Therapeutics?

Cerevel Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 6,020,000 shares, an increase of 43.0% from the January 15th total of 4,210,000 shares. Based on an average daily volume of 2,620,000 shares, the short-interest ratio is presently 2.3 days. Approximately 7.0% of the company's shares are short sold.
View Cerevel Therapeutics' Short Interest
.

When is Cerevel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our CERE earnings forecast
.

How were Cerevel Therapeutics' earnings last quarter?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) announced its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.02. During the same quarter last year, the firm earned ($0.66) earnings per share.

What ETFs hold Cerevel Therapeutics' stock?

ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), iShares Neuroscience and Healthcare ETF (IBRN) and Principal Healthcare Innovators ETF (BTEC).Harbor Health Care ETF (MEDI).

What other stocks do shareholders of Cerevel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO).

Who are Cerevel Therapeutics' major shareholders?

Cerevel Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Bain Capital Investors LLC (36.43%), Avoro Capital Advisors LLC (4.19%), Vanguard Group Inc. (4.09%), FIL Ltd (1.53%), Alpine Associates Management Inc. (0.91%) and Voloridge Investment Management LLC (0.50%). Insiders that own company stock include Abraham Ceesay, Bain Capital Investors Llc, Deval L Patrick, Gabrielle Sulzberger, John Renger, Kenneth Dipietro, Marijn E Dekkers, Mark Bodenrader, N Anthony Coles, Paul D Burgess, Perceptive Advisors Llc, Ramiro Sanchez, Ronald C Renaud Jr, Scott Akamine and Susan Altschuller.
View institutional ownership trends
.

How do I buy shares of Cerevel Therapeutics?

Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CERE) was last updated on 2/23/2024 by MarketBeat.com Staff